Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Bladder Cancer: Update Bulletin # 2 [February 2019]

Product Code:
596201039
Publication Date:
February 2019
Format:
PDF
Price:
£1,140

This edition presents key opinion leader (KOL) views on recent developments in the bladder cancer market. Topics covered include: UroGen Pharma announcing positive topline data from the pivotal Phase III OLYMPUS study assessing MitoGel (mitomycin gel; UGN-101) for low-grade upper tract urothelial cancer (LGUTUC); Rainier Therapeutics (formerly BioClin Therapeutics) announcing that data from the Phase II FIERCE-21 study assessing vofatamab, the company’s selective fibroblast growth factor receptor 3 (FGFR3) inhibitor, would be presented at the 2019 ASCO Genitourinary Cancers Symposium; and Basilea announcing a collaboration with Roche to explore a combination of derazantinib, its oral multikinase inhibitor of FGFR, with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in patients with urothelial cancer.

Business Questions:

• What are the experts’ reactions to the data from MitoGel’s Phase III OLYMPUS trial? 
• According to KOLs, how viable is MitoGel as a future treatment for LGUTUCBP3
• What role do KOLs think the FGFR3 inhibitor vofatamab will play as a treatment for bladder cancer?
• Which of vofatamab’s clinical trials are KOLs most excited about?
• What is the potential of a FGFR inhibitor and immune checkpoint inhibitor combination?v
• Where could the combination of derazantinib and Tecentriq be utilised in the treatment of bladder cancer?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved